+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Not Verified

Predoctoral Fellowship in Drug Delivery

PhRMA Foundation

The PhRMA Foundation Predoctoral Fellowship in Drug Delivery provides support for promising students (U.S. and non-U.S. citizens) in advanced stages of training and thesis research in drug delivery research, including basic pharmaceutics, biopharmaceutics, pharmaceutical technology, pharmaceutical biotechnology, or biomedical engineering.

Program Vision

Delivering today’s increasingly complex drugs to patients demands novel approaches in technology development, formulation, manufacturing, as well as prediction and demonstration of in vivo performance. The PhRMA Foundation seeks to fund therapeutically relevant research that optimizes drug composition, dosage, and delivery to make treatments clinically viable, safer, more effective, and/or easier to manage for patients.

Scope of Research

Research areas could include, but are not limited to:

Formulation composition, drug dosage, and delivery modalities/technologies that enable desired pharmacokinetics (PK) and pharmacodynamics (PD) of drugs, including emerging molecular and biological modalities
Development of CMC (Chemistry, Manufacturing, and Controls) processes that achieve enhanced product quality of challenging chemical entities (e.g., poorly soluble drugs, large molecules, cell-based constructs)
Predictive approaches (e.g., modeling, simulation, data analytics, and machine and deep learning) that seek to achieve in vitro and in vivo correlation; bridge a drug’s critical quality attributes and in vivo performance (PK, efficacy, and toxicity); and facilitate assessment of toxicities and side effects of a drug delivery system

Requirements

Proposals must include a clearly defined therapeutic payload and target tissue, as well as rationale for dosing and PK/PD feasibility. When possible, a project should include a plan for biodistribution and a clear explanation of functional delivery efficiency. Research applicable to multiple drug modalities will be prioritized.

Computational approaches must include a clear and feasible plan for translational validation to human-relevant systems. Proposals that involve AI approaches (i.e., data-driven ML/DL) must clearly document and reference the methodology, explain the data curation process (sources, quality, quantity), and detail the validation process.

Nonresponsive

Proposals framed as platform development without a payload, disease context, or feasibility path will not be considered.

FUNDING

The PhRMA Foundation Predoctoral Fellowship in Drug Delivery provides $30,000 in stipend support per year for 12, 18, or 24 months.
To receive funding beyond the first 12 months, awardees must provide the PhRMA Foundation with a satisfactory progress report upon completion of the first 10 months of funding. In addition, awardees must provide a letter from their thesis advisor, confirming that satisfactory progress is being made.
Funding is conditional upon the awardee’s continued enrollment with the university, which will be assessed on a quarterly basis prior to payment. The awardee is required to notify the PhRMA Foundation if they leave the university or defend early.
Payments will be made directly to the university on behalf of the awardee, with the understanding that the university will administer the funds.
This award is intended solely as a stipend and may not be used otherwise. Funds may not be used for tuition, fringe benefits, or indirect costs to the university.
Within the yearly award amount of $30,000, up to $1,000 per year may be used for incidentals directly associated with thesis research preparation or travel to a scientific conference in the United States.
Funding may begin as early as January 1, 2027, or on the first day of any month thereafter, up to and including August 1, 2027.
A financial report (separate from the 10-month progress report) will be required upon completion of the first 12 months of funding.
A final progress report and financial report will be required within 60 days of the fellowship’s conclusion.
Unspent funds are to be returned to the PhRMA Foundation.
Any changes to the proposed project must be approved by the PhRMA Foundation.
These funds are non-transferable.

AI Based Application Success Predictor

🧬 1. Strong Alignment with Core Research Areas (Non-Negotiable)

The PhRMA Foundation funds only specific domains:

Drug discovery
Drug delivery
Translational medicine
Health outcomes/value assessment

👉 Projects outside these areas → low success probability

🎯 2. Career Development Potential (Top Predictor)

Core mission:
- “Catalyze the careers of promising researchers”
Evaluation heavily weighs:
- Career trajectory
- Potential for independence

👉 Key question:
“Will this applicant become a future leader in biomedical research?”

🔄 3. Strong Translational & Therapeutic Relevance (Critical)

Preference for:
- Research that improves:
  - Drug effectiveness
  - Delivery
  - Clinical outcomes

👉 Pure basic science is less competitive unless clearly linked to therapy

🚀 4. Innovation in Therapeutics & Drug Development

High success for:
- Next-generation therapeutics (e.g., gene therapy, biologics)
Funders favor:
- High-risk, high-reward innovation

👉 Incremental work is less competitive

🔬 5. Strong Scientific Merit & Rigor

Proposals are:
- Peer-reviewed competitively
Must include:
- Clear hypothesis
- Robust methodology
- Mechanistic insight

👉 Weak design = major rejection reason

🧪 6. Clear Translational Pathway & Impact

Must demonstrate:
- Path toward:
  - Clinical application
  - Drug development

👉 “How will this improve medicines?” is central

👩‍🔬 7. Early-Career Investigator Focus (Major Priority)

Programs target:
- Predoctoral
- Postdoctoral
- Junior faculty researchers

👉 Strong advantage for:

Early-stage investigators with growth potential

🤝 8. Multidisciplinary & Industry-Relevant Approach

Encourages:
- Collaboration across:
  - Biology
  - Chemistry
  - Engineering
  - Clinical sciences

👉 Industry relevance (drug pipeline) improves competitiveness

📊 9. Feasible, Well-Structured Research Plan

Grants are:
- Time-limited (1–2 years typical)
Must include:
- Clear aims
- Milestones
- Achievable outcomes

👉 Overly ambitious proposals are often rejected

📈 10. Potential for Future Funding & Career Growth

Strong track record:
- ~71% of awardees later secure NIH funding

👉 Projects that:

Generate preliminary data
Lead to major grants
→ score highly

📊 Summary: Key Predictors (Ranked)

Highest impact factors:

Alignment with drug-related research areas
Career development potential
Translational/therapeutic relevance

Moderate predictors:
4. Innovation
5. Scientific rigor
6. Feasibility

Supporting factors:
7. Multidisciplinary approach
8. Early-career stage
9. Future funding potential

💡 Insider Insight

Compared to NIH or disease-specific funders:

PhRMA Foundation is:
👉 career-development + drug-focused
👉 strongly aligned with pharmaceutical innovation pipeline

👉 Winning formula:
Early-career researcher + translational drug-focused idea + strong mentorship + feasible plan

✔️ What wins:

Drug discovery/delivery innovation
Translational projects with clinical relevance
Strong career development plan

❌ What struggles:

Pure basic science without therapeutic link
Weak career trajectory
Poor alignment with pharma-focused themes

Specialties

Pharmaceuticals

Eligibility Requirements

Applicants (U.S. and non-U.S. citizens) must attend an accredited U.S. university as full-time, in-residence students.
Individuals just beginning graduate school should not apply. Applicants must have completed most of their pre-thesis requirements (at least two years of coursework) and be engaged in thesis research as PhD candidates by the time the award is activated. Award activation can begin as early as January 1, 2027, or as late as August 1, 2027.
Applicants who expect to complete their PhD before December 1, 2027, are ineligible.
Applicants enrolled in MD/PhD programs should not be engaged in required clinical coursework or clerkships while the fellowship is active. Fellows are expected to devote full time (including summers) to their research.
Applicants who have not authored a publication or presented a poster are ineligible.
Applicants currently funded on an institutional training grant (e.g., NIH TL1, T32, T90, or T35 awards or a nonprofit/professional society equivalent) may apply if they state they will forgo the institutional training slot if funded by a PhRMA Foundation predoctoral award.
Applicants are ineligible if they are the recipient of an NIH-F award.
An individual may not simultaneously hold another funding mechanism providing stipend support while the PhRMA Foundation predoctoral fellowship is active. If necessary, the university may supplement the Foundation’s award to a level that is consistent with other predoctoral fellowships it offers.
The predoctoral fellowship is not intended to fund work already supported by a principal investigator’s active grants.
Only one applicant per lab may apply in the Drug Delivery Program. Labs must select either a predoc, a postdoc, or a faculty member.

Sponsor Details

Sponsor Institute/Organizations: PhRMA Foundation

Sponsor Type: Corporate/Non-Profit

Address: 670 Maine Avenue SW, Suite 1000 Washington DC, 20024-3556

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity